The National Cancer Institute (NCI) is offering the ETCTN Pharmacokinetic Resource Laboratories Grant to establish laboratories supporting the Experimental Therapeutics Clinical Trials Network (ETCTN). These laboratories will focus on specimen collection and analysis of pharmacokinetic endpoints, drug interactions, and food effects in NCI Investigational New Drug (IND) studies. The goal is to enhance the clinical development of NCI-IND agents by understanding their pharmacokinetic behavior. Applicants must submit U24 cooperative agreement applications for conducting pharmacokinetic studies in early phase clinical trials filed to the IND applications in NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Closing date: May 22, 2019.
Opportunity ID: 311913
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-19-008 |
| Funding Opportunity Title: | The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 10, 2019 |
| Last Updated Date: | Jan 10, 2019 |
| Original Closing Date for Applications: | May 22, 2019 |
| Current Closing Date for Applications: | May 22, 2019 |
| Archive Date: | Jun 27, 2019 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $320,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Private institutions of higher education Small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) State governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts County governments City or township governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA solicits U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00247420 | Apr 22, 2019 | May 22, 2019 | View |
Package 1
Mandatory forms
311913 RR_SF424_2_0-2.0.pdf
311913 PHS398_CoverPageSupplement_4_0-4.0.pdf
311913 RR_OtherProjectInfo_1_4-1.4.pdf
311913 PerformanceSite_2_0-2.0.pdf
311913 RR_KeyPersonExpanded_2_0-2.0.pdf
311913 RR_Budget10_1_4-1.4.pdf
311913 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
311913 RR_SubawardBudget10_30_1_4-1.4.pdf
311913 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
